ArticleBMC medical imaging2025
The baseline
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCongenital neuroblastoma represents a distinct subtype of neuroblastoma that originates during fetal and neonatal development. Limited research has been conducted on the prognostic significance of baseline Fluorine-18-Fluorodeoxyglucose positron emission tomography/computerized tomography (
methodsA retrospective collection was performed using imaging and clinical data from pediatric patients diagnosed with congenital neuroblastoma who underwent
resultsA total of 28 pediatric patients with congenital neuroblastoma were included in the study. There are 26 patients exhibited elevated serum NSE levels, 25 patients exhibited elevated serum LDH levels. Only 3 patients had MYCN amplification. 5 patients had 11q23 aberration. Primary tumors were located in the abdomen or mediastinum in all but two patients, who had pelvic and cervical involvement. All primary tumor had high FDG uptake. 6 patients had liver metastases, and 1 patient showed normal FDG uptake. 4 patients had bone marrow metastases, all of them showed high FDG uptake. With a median follow-up of 711 days, 23 patients had progression free survival, and 5 cases of recurrence.
conclusionOur study showed that the prognosis of congenital neuroblastoma was generally favorable and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.